News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
Augurex featured in a RheumNow Therapeutic Update with Dr. Walter Maksymowych
Augurex is featured in a RheumNow Therapeutic Update with Dr. Walter Maksymowych, highlighting the role of 14-3-3eta across the RA care continuum. In this feature, Dr. Walter Maksymowych explores how 14-3-3eta helps close diagnostic and monitoring gaps in RA care....
Augurex Announces UK Conformity Assessed (UKCA) Authorization for JOINTstat®, Expanding Access to Cutting-Edge Rheumatoid Arthritis Testing in Great Britain
Augurex has received UK Conformity Assessed marking for JOINTstat®, authorizing its use in Great Britain for rheumatoid arthritis diagnosis and management. JOINTstat® is a well-established rheumatoid arthritis blood test in North America, approved by Health Canada and...
Augurex attends the TRS 2025 Annual Meeting
Vancouver, Canada – February 21, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced its participation in the Tennessee Rheumatology Society (TRS) 2025 Annual Meeting taking place from February 28 – March 1 in...
Augurex attends the Canadian Rheumatology Association (CRA) 2025 Annual Scientific Meeting
Vancouver, Canada – February 19, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, is pleased to announce its participation in the Canadian Rheumatology Association (CRA) 2025 Annual Scientific Meeting, taking place February 26 –...
Augurex Attending RheumNow Live 2025
Vancouver, Canada – February 3, 2025 – Augurex is excited to announce that it will attend the RheumNow Live 2025 conference, a premier event bringing together leading rheumatologists and researchers to discuss the latest advancements in rheumatic disease diagnostics,...
Biomarkers in Axial Spondyloarthritis: Dr. Walter Maksymowych on Spondycast
Vancouver, Canada – January 28, 2025 - The Spondylitis Association of America (SAA) invited Dr. Walter Maksymowych to join their latest episode of Spondycast, where he discusses the growing role of 14-3-3eta autoantibodies (Anti-14-3-3eta Multiplex) in the diagnosis...
Featured in SAA’s eSUN Newsletter: Advancing AxSpA Diagnosis with Anti-14-3-3eta Multiplex
Vancouver, Canada – January 27, 2025 – Delays in diagnosing axial spondyloarthritis (axSpA) have been a persistent challenge, with many patients waiting 7 to 10 years for an accurate diagnosis. These delays can lead to missed opportunities for early treatment and a...
Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management
Quest to introduce lab-developed test based on Augurex 14-3-3η (eta) biomarker to U.S. physicians later this month Vancouver, Canada – November 15, 2024 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it...
Augurex and New Day Diagnostics Announce Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents; Enabling a First-In-Class Diagnostic Test for Axial Spondyloarthritis
Augurex launches Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA) by New Day Diagnostics. The new laboratory developed test, which uses Anti-14-3-3eta...
Canada’s Most Powerful Women: Top 100 Current Winners
Augurex CEO Norma Biln was awarded Canada's Most Powerful Women: Top 100 Award for her extraordinary leadership and continued drive to inspire others. The Top 100 Award Winner community now includes 1,005 remarkable women who together celebrate accomplishments, share...
Children get arthritis too; Data on a blood test to help characterize JIA and its subtypes.
At the world’s premier arthritis conference, the American College of Rheumatology Annual Meeting (ACR), taking place in San Diego on November 3rd-8th, leading investigators from the United States, Canada and Egypt will present new data on the 14-3-3η blood test....
USPTO Issues 14-3-3η Patent: Good News for RA Patients
NEWS RELEASE | OCTOBER 17, 2017 Vancouver, BC — Augurex Life Sciences Corp is proud to announce that 14-3-3η, a novel rheumatoid arthritis (RA) biomarker, is paving a future for better patient outcomes. Today the U.S Patent and Trademark Office (USPTO) has issued...
Explaining The “Why”; 14-3-3η’s Biological Role As A Basis For Its Clinical Utility
Vancouver, BC – June 13, 2017. At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Madrid, Spain on June 14-17, investigators present the continued understanding of 14-3-3η's role in rheumatoid...
Serial 14-3-3η testing: informing RA flare and joint damage risk as you treat-to-target
Vancouver, BC – April 18, 2017. At the premier Asia-Pacific rheumatology conference, the Japan College of Rheumatology Annual Scientific Meeting (JCR), taking place in Fukuoka, Japan on April 20-22, international investigators from the United States, Canada, and...
Accelerating the Transformation of Patient Care
Please see the Genome BC news release from last week. Augurex is proud of and appreciates the ongoing support that we receive from provincial and federal government programs to expedite JOINTstat™ access to patients worldwide. Augurex is recognized as an emerging...
14-3-3η: Informing the RA Continuum of Care
14-3-3η Informs the RA Continuum of Care Vancouver, BC – October 28, 2016. At the world’s premier rheumatology conference, the American College of Rheumatology Annual Meeting (ACR) in Washington, DC, November 11-16, international investigators from Sweden, the United...
JOINTstat™ (14-3-3η); New Possibilities in RA
Augurex Life Sciences Corp. announces big leaps forward for applications of the JOINTstat™ (14-3-3η) blood test in rheumatoid arthritis (RA). Disease management is quickly moving upstream toward earlier identification and treatment, in some cases even pre-disease, and...
JOINTstat™ cleared for clinical use in Australia by the Therapeutic Goods Administration (TGA)
Augurex is pleased to announce that the JOINTstat™ (14-3-3η) blood test has been cleared for clinical use in Australia by the Therapeutic Goods Administration (TGA). The test is indicated for the diagnosis of rheumatoid arthritis (RA) and the assessment and monitoring...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Home
Products
Science
About
News
Careers
Contact

















